Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,793 | -24,952 | -24,274 | -4,468 | -2,257 |
| Income taxes - deferred | N/A | -852 | -852 | N/A | N/A |
| Accounts payable and accrued liabilities | 112 | 689 | 371 | 56 | 191 |
| Other Working Capital | 582 | 1,522 | 1,331 | 833 | 331 |
| Other Operating Activity | 300 | 18,479 | 18,722 | 286 | -38 |
| Operating Cash Flow | $-799 | $-5,114 | $-4,701 | $-3,294 | $-1,772 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | 2,052 | 2,052 | 2,000 | N/A |
| Other Financing Activity | 0 | 1,633 | 1,646 | -165 | 1,853 |
| Financing Cash Flow | $1,000 | $3,685 | $3,698 | $1,835 | $1,853 |
| Beginning Cash Position | 102 | 1,531 | 1,531 | 1,531 | 1,531 |
| End Cash Position | 303 | 102 | 528 | 72 | 1,612 |
| Net Cash Flow | $201 | $-1,429 | $-1,003 | $-1,459 | $81 |
| Free Cash Flow | |||||
| Operating Cash Flow | -799 | -5,114 | -4,701 | -3,294 | -1,772 |
| Free Cash Flow | -799 | -5,114 | -4,701 | -3,294 | -1,772 |